综合一区欧美国产,99国产麻豆免费精品,九九精品黄色录像,亚洲激情青青草,久久亚洲熟妇熟,中文字幕av在线播放,国产一区二区卡,九九久久国产精品,久久精品视频免费

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Latest

Eli Lilly promotes new drug at CIIE

By SHI JING in Shanghai | chinadaily.com.cn | Updated: 2019-11-09 09:43
Share
Share - WeChat

Indianapolis-headquartered pharmaceutical company Eli Lilly and Company attended the second China International Import Expo with its latest medicine Taltz to moderate severe plaque psoriasis.

During the news conference on Thursday, a total of 17 Chinese domestic pharmaceutical companies signed intention agreements with Eli Lilly for the purchase of Taltz. The medicine has been approved by China's National Products Administration in September.

Eli Lilly and Company was not present at last year's CIIE. Julio Gay-Ger, president and general manager of Lilly China, said that they "were positively surprised by the huge success that CIIE had last year".

"So we really want to be part of the CIIE in the second year. We have had in the last 12 months five new molecular entities launched in China. This is very close to our record. More importantly, we have up to 40 new launches in the next seven to 10 years. We are bringing innovations to Chinese patients which will make a huge difference to them," he said.

Gay-Ger said the company has had expectations for Lilly China's sales and business growth.

"China is the second-largest pharmaceutical market in the world today. It is supposed to be the No 1 pharmaceutical market in the future. It is our top priority market and that is why we are investing so heavily and bringing so much innovation here," he said.

Lilly set up its Shanghai office in 1918, which was the first overseas office for the US pharmaceutical company. Lilly China's overall growth rate for the first half of 2019 exceeded 30 percent, reaching a record high throughout the company's 101-year history in China.

Ever since 2013, Lilly has invested about $320 million to build an insulin production facility in Suzhou. The site is set to be an integral part of Lilly's global supply chain, providing insulin products for China, Europe and other markets across the world in 2019.

"In the future, we can have new launches in China simultaneously or almost simultaneously with other markets in the world. That progress is in part because of the great reform that government is taking, which offers great opportunity to have all that happen," he said.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
正安县| 临城县| 武隆县| 大姚县| 禄丰县| 阳西县| 德庆县| 化德县| 郑州市| 淳化县| 镶黄旗| 大悟县| 博野县| 北海市| 定结县| 永吉县| 响水县| 福州市| 新丰县| 仁化县| 商丘市| 博白县| 舞阳县| 东平县| 东阿县| 吉林市| 怀安县| 镇康县| 杭州市| 丁青县| 岳西县| 商水县| 乐山市| 察雅县| 铁岭县| 册亨县| 万宁市| 长宁区| 阿坝县| 京山县| 曲周县|